top of page

Complex enterprise engagements that make the difference.

Pipeline & Deal Velocity

Who is it for?

Founders and CEOs managing high-stakes enterprise deals without a senior commercial structure around them.

When to use?

When you're closing complex, high-value deals but pricing conversations, prioritisation, and key hires are all landing on the CEO.

2026-05-06

Proven product, real hospital deployments, strong supplier interest - and a CEO carrying every major commercial conversation alone. This is how MediShout moved from early traction to seven-figure ARR by fixing the commercial execution layer, not the product.

When I met MediShout, they had already proven their solution works. Their platform helps medical device manufacturers track and manage their products through hospitals - hospitals were using it, early supplier relationships were solid, real value was being delivered.

But navigating complex commercial conversations with industry giants required different skills. The challenge wasn't product-market fit. It was making fast, high-stakes strategic decisions, on key deals with complex pricing models, and multi-year commitments that could make or break the business.


Results

Ash Kalraiya, CEO and Founder, and I worked closely together with the following results.

  • ARR Reached well into seven figures with a 10x growth rate.

  • The business developed from the UK only to include European and US customers.

  • Expansion across more hospitals and increasing traction with top-20 and top-5 manufacturers

  • Far greater confidence when navigating pricing and multi-year agreements

  • A capable commercial team through targeted hiring

  • Sharper prioritisation of suppliers and opportunities, reducing distraction and protecting resources

These outcomes reflect a more deliberate, structured, and scalable commercial motion.


The Starting Point

When I started working with MediShout the starting point was:

  • Clear market pull and early deployments across hospitals

  • Strong supplier interest from some of the world’s largest medical-device manufacturers

  • All major commercial conversations led directly by the CEO

  • Simultaneous need to scale existing customers while winning new ones

  • A requirement to maximise market position quickly with limited bandwidth

How We Worked Together

1. Navigating high-stakes commercial conversations

We prepared for major supplier negotiations - pricing, multi-year commitments, and partnership models. This included framing value, structuring meetings, and defining negotiation paths that protected MediShout while enabling scale.

2. Strengthening strategic decision-making

We built a weighted pipeline model to assess ARR potential, strategic value, scalability, and operational complexity. This created clarity on where to focus, where to pause, and where to push back - moving from reactive execution to disciplined prioritisation.

3. Building the commercial team

I supported the CEO through major sales hires, refining role profiles, evaluating candidates, and strengthening the GTM capability around him.


Generalising the learnings:

As companies scale, three themes repeatedly deliver the most leverage:

  • Structured preparation for the highest-stakes conversations

  • Effective prioritisation to invest time where it has meaningful impact

  • Hiring bar aligned with the commercial motion you’re building

These levers create discipline and control when complexity increases, and it always increases faster than headcount.


CEO perspective

“Your support has fundamentally changed how we scale. We’re navigating the largest suppliers in our industry with more confidence, making better commercial decisions, and driving growth in a way we weren’t achieving before” Ash Kalraiya, CEO and Founder, Medishout

From your email “Thanks for all the amazing support and help this year as always, it's massively helped us grow to the position we're in

If this was useful, stay close to the thinking.

Get practical GTM insights and strategic breakdowns in your inbox. Weekly.

Related Posts

Pipeline & Deal Velocity

9 Feb 2026

What Don't You Know About Your Deals?

Deal risk often hides in what the team assumes rather than what it knows. This piece shows how to find the blind spots that distort pipeline confidence.

Discovery, Pipeline & Deal Velocity

26 Jan 2026

Engage the Economic Buyer earlier

Deals often stall because the real decision-maker enters too late. This piece explains why engaging the economic buyer earlier improves deal quality and speed.

Pipeline & Deal Velocity

18 Jan 2026

Too many deals drift quarter after quarter with no real progress.

Too many pipelines look healthy because stalled deals are treated as active opportunities. This article explores why deals drift, how false progress shows up, and what to do before another quarter slips away.

All Blog Posts →

Relevant resources

Tools and insights for improving your revenue engine

Demo Training

Coach winning demos

Discovery Training

Qualify deeper, faster

AE Toolkit

Hire top performers

See more resources 

bottom of page